These results underscore a significant increase in pemphigus risk among patients treated with PD-1, PD-1L, and CTLA-4 inhibitors, suggesting that ICIs may induce autoimmune responses through mechanisms such as immune dysregulation or regulatory T cell depletion.1 Here, CTLA4 is linked to pemphigus.